Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
August 9, 2021

Coronavirus company news summary – Harvard and MIT researchers develop saliva-based test – Qiagen’s portable antigen test gets FDA EUA

By Chloe Kent

BD and CerTest Biotec have received the European CE mark for a molecular test designed to identify Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) SARS-CoV-2 variants. The VIASURE SARS-CoV-2 Variant Real Time PCR Detection Kit can be used with VIASURE SARS-CoV-2 (N1+N2) Real Time PCR Detection Kit or as a reflex test for variant detection from a positive sample.

A team of researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University, the Massachusetts Institute of Technology (MIT) and multiple hospitals in the Boston region have developed a saliva-based self-test for the SARS-CoV-2 virus and its variants. The CRISPR-based test is said to be cost-effective and meant for at-home use. Named miSHERLOCK, the diagnostic device offers results that are read and validated using a related smartphone app in one hour.

Qiagen has obtained Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for the use of its portable QIAreach SARS CoV-2 Antigen Test. QIAreach can identify SARS-CoV-2 antigens in two to 15 minutes in individuals with active infections. The test is capable of processing approximately 30 swab samples an hour and delivers digital results.

Related Companies

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU